← Back to Search

Behavioural Intervention

PAC Intervention Arm for Heart Failure (PATHFINDER Trial)

N/A

Recruiting

Led By David Lanfear, MD

Research Sponsored by Henry Ford Health System

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Currently hospitalized with plan to be discharged to home

Primary discharge diagnosis heart failure

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 and 90 days post-enrollment

Awards & highlights

PATHFINDER Trial Summary

This trial, called PATHFINDER, is part of a larger project called ACHIEVE GREATER. The goal of the project is to reduce health disparities and inequality between Black and White individuals in

Who is the study for?

This trial is for heart failure patients currently hospitalized and soon to be discharged home, with specific blood test results indicating heart failure severity. They must be able to participate fully in the study without long travel plans.Check my eligibility

What is being tested?

The ACHIEVE PATHFINDER trial tests if portable air cleaners (PAC) given at hospital discharge can help manage heart failure. Patients are randomly assigned to receive a PAC or no intervention; some PACs have filters.See study design

What are the potential side effects?

Since this trial involves non-invasive interventions like portable air cleaners, there are minimal expected side effects compared to drug treatments. Any potential discomfort would likely come from inconvenience or noise.

PATHFINDER Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am in the hospital now but will be going home soon.

Select...

My main diagnosis when discharged was heart failure.

PATHFINDER Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 and 90 days post-enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 and 90 days post-enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 and 90 days post-enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The impact of PAC use for 90 days after hospital discharge for HF compared to sham on NTproBNP level.

Secondary outcome measures

The effect of PAC use on clinical events (death) in the active PAC group versus sham group

The effect of PAC use on clinical events (hospitalization) in the active PAC group versus sham group

The effect of PAC use on home PM2.5 levels in active PAC group versus sham group

Other outcome measures

Impact of PAC on hsCRP

Impact of PAC on hsTroponin

Impact of PAC use on health status

PATHFINDER Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: PAC Intervention ArmActive Control1 Intervention

Participants randomized to the interventional arm will be given 2 PAC units with HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor. Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed. Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters.

Group II: Control non-interventional ArmPlacebo Group1 Intervention

Participants randomized to the non-interventional arm will be given 2 PAC units without HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor. Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed. Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Henry Ford Health SystemLead Sponsor

300 Previous Clinical Trials

2,099,482 Total Patients Enrolled

9 Trials studying Heart Failure

1,005 Patients Enrolled for Heart Failure

Wayne State UniversityOTHER

309 Previous Clinical Trials

108,875 Total Patients Enrolled

10 Trials studying Heart Failure

4,888 Patients Enrolled for Heart Failure

David Lanfear, MDPrincipal InvestigatorHenry Ford Health

1 Previous Clinical Trials

105 Total Patients Enrolled

1 Trials studying Heart Failure

105 Patients Enrolled for Heart Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment phase of this medical study currently ongoing?

"Indeed, as stated on clinicaltrials.gov, this trial is currently in the process of enrolling patients. The initial posting for the study was made on December 18th, 2023, and it was last updated on January 10th, 2024."

Answered by AI

What is the upper limit on the number of participants engaged in this clinical investigation?

"Indeed, the information available on clinicaltrials.gov indicates that this ongoing clinical trial is actively seeking eligible participants. The trial was initially posted on December 18th, 2023 and recently updated on January 10th, 2024. A total of 400 patients will be enrolled at a single designated site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Project 4: ACHIEVE PATHFINDER

David Lanfear 2023. "Project 4: ACHIEVE PATHFINDER". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06070428.